Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target
Creators
- Nie, Qixing1
- Luo, Xi1
- Gonzalez, Frank J.2
- Wang, Kai1
- Zhang, Zhiwei1
- Hang, Jing3
- Liu, Jia4
- Guo, Fusheng1
- Ding, Yong1
- Li, Meng1
- Nie, Qi-Xing1
- Lin, Jun1
- Zhuo, Yingying1
- Sun, Lulu2
- Zhong, Qihang3
- Ye, Chuan1
- Yun, Chuyu1
- Zhang, Yi1
- Wang, Jue1
- Bao, Rui5
- Pang, Yanli3
- Wang, Guang4
- Gonzalez, Frank2
- Lei, Xiaoguang1
- Qiao, Jie3
- Jiang, Changtao1
- 1. Peking University
- 2. National Cancer Institute
- 3. Peking University Third Hospital
- 4. Capital Medical University
- 5. West China Hospital of Sichuan University
Description
A mechanistic understanding of how microbial proteins affect the host could yield deeper insights into gut microbiota–host cross-talk. We developed an enzyme activity-screening platform to investigate how gut microbiota-derived enzymes might influence host physiology. We discovered that dipeptidyl peptidase 4 (DPP4) is expressed by specific bacterial taxa of the microbiota. Microbial DPP4 was able to decrease the active glucagon like peptide-1 (GLP-1) and disrupt glucose metabolism in mice with a leaky gut. Furthermore, the current drugs targeting human DPP4, including sitagliptin, had little effect on microbial DPP4. Using high-throughput screening, we identified daurisoline-d4 (Dau-d4) as a selective microbial DPP4 inhibitor that improves glucose tolerance in diabetic mice.
Notes
Files
Files
(6.0 MB)
Name | Size | Download all |
---|---|---|
md5:88a343cd0fd2e0519489ccc572b6bdbf
|
1.3 kB | Download |
md5:36c373f87bf8e43bf50e3a10227e1be9
|
4.4 MB | Download |
md5:4960fcbe2019a1b4216dc1870469195e
|
1.6 MB | Download |
Additional details
Related works
- Is cited by
- 10.1126/science.add5787 (DOI)
- Is derived from
- 10.5061/dryad.b2rbnzsmq (DOI)